{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:03:52Z","timestamp":1792854232915,"version":"4.5.0"},"reference-count":68,"publisher":"The Korean Association for the Study of the Liver","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":201,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"Cedars-Sinai Cancer and Cancer Biology Program discovery fund","award":["R01 HL149946"],"award-info":[{"award-number":["R01 HL149946"]}]},{"name":"Cedars-Sinai Cancer and Cancer Biology Program discovery fund","award":["R01 CA273925"],"award-info":[{"award-number":["R01 CA273925"]}]},{"name":"Surface Oncology Inc"},{"name":"American College of Gastroenterology Junior Faculty Development Award"},{"name":"Department of Defense Peer Reviewed Cancer Research Program Career Development Award","award":["CA191051"],"award-info":[{"award-number":["CA191051"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA259534"],"award-info":[{"award-number":["K08CA259534"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:p>Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and is usually precipitated by chronic viral infections (hepatitis B and C), non-alcoholic steatohepatitis, heavy alcohol use, and other factors which may lead to chronic inflammation and cirrhosis of the liver. There have been significant advances in the systemic treatment options for HCC over the past decades, with several approvals of both immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with preserved liver function. These advances have led to improvement in survival outcomes, with expected survival of greater than 18 months, in those with sensitive tumors, adequate liver function, and those functionally fit to receive sequential therapies. Several ongoing and promising trials are now evaluating combinational strategies with novel systemic agents and combinations of systemic therapy with locoregional therapy. In view of these trials, further advances in the treatment of HCC are foreseen in the near future.<\/jats:p>","DOI":"10.3350\/cmh.2023.0125","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T19:15:35Z","timestamp":1690139735000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Recent advances in the management of hepatocellular carcinoma"],"prefix":"10.3350","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-8479","authenticated-orcid":true,"given":"Kamya","family":"Sankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Osipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Kosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas N.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Hendifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina K.","family":"Koltsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9825","authenticated-orcid":true,"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab079"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0186-y"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31811"},{"key":"ref5","volume-title":""},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3544"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290145"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745"},{"key":"ref14","first-page":"EVIDoa2100070","volume-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","author":"Abou-Alfa","year":"2022"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32453-9"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1717002"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30937-9"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31046-2"},{"key":"ref20","first-page":"940","volume-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","author":"Zhu","year":"2018"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00604-5"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01307"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00620"},{"key":"ref24","first-page":"267","volume-title":"IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab+ bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma","author":"Finn","year":"2021"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.024"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30889"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716948"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26094"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3064"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_95"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3541"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.031"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00326-6"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.032"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01678-1"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1172\/jci67313"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157164"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-018-1993-1"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01157"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.798832"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.09.052"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.04.016"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02787-1"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01308"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1352"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s358658"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315485"},{"key":"ref56","first-page":"TPS629","volume-title":"(2023). A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+\/-BEAT","author":"Iyer","year":"2023"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00392"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05920-8"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00234-4"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2020-ct284"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy282.166"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0162"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-ct003"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0025"},{"key":"ref66","first-page":"1000","volume-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study","author":"D\u2019Alessio","year":"2022"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15551"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.07.05"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2023-0125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2023.0125","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2023-0125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T23:45:49Z","timestamp":1704411949000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2023.0125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2023.0125","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"assertion":[{"value":"2023-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}